Rituximab is a monoclonal anti-CD20 B-cell depletion therapy, and it is considered in a multi-IST refractory AChR-MG in a case-by-case basis as the response rates were not as consistent as in anti-MuSK MG. This evidence concerns the gene MUSK and myasthenia gravis.